PatientID: HIVDR-800-23

Sebuttemba 27, 2023

## Color Code

HR: High-Level Resistance
LR: Low-Level Resistance
IR: Intermediate Resistance

S: Susceptible

DRUG.CLASS	DRUG	RESISTANCE.PROFILE	DRMS.above.20.percent.prevalence	
PI	ATV	S		
	DRV	$\mathbf{S}$		
	FPV	PLR		
	IDV	${f S}$	;L33LF	
	LPV	$\mathbf{S}$		
	NFV	$\operatorname{PLR}$		
	SQV	${f S}$		
	TPV	$\operatorname{PLR}$		
NRTI	ABC	IR		
	AZT	$_{ m HR}$	D67N;K70R;M184V;K219Q	
	D4T	IR		
	DDI	IR		
	FTC	$_{ m HR}$		
	LMV	$_{ m HR}$		
	TDF	$\operatorname{LR}$		
NNRTI	DOR	${f S}$		
	EFV	${f S}$		
	ETR	$\mathbf{S}$		
	NVP	${f S}$		
	RPV	${f S}$		
INSTI	BIC	S		
	CAB	S		
	DTG	$\mathbf{S}$		
	EVG	$\mathbf{S}$		
	RAL	${f S}$		

## Appendix

## Drug abbreviations in full

DRUG.CLASS	ABBREVIATION	DRUG.NAME
	ATV	Atazanavir
	DRV	Darunavir
	FPV	Fosamprenavir
PI	IDV	Indinavir
11	LPV	Lopinavir
	NFV	Nelfinavir
	SQV	Saquinavir
	TPV	Tipranavir
	ABC	Abacavir
	AZT	Azidothymidine
	DFT	Stavudine
NRTI	DDI	Didanosine
	FTC	Emtricitabine
	LMV	Lamivudine
	TDF	Tenofovir
	DOR	Doravirine
	EFV	Efavirenz
NNRTI	ETR	Etravirine
	NVP	Nevirapine
	RPV	Rilpivirine
	BIC	Bictegravir
	CAB	Cabotegravir
INSTI	DTG	Dolutegravir
	EVG	Elvitegravir
	RAL	Raltegravir

## Comments

DRUG.CLASS	COMMENTS
PI	
	L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In
	combination with other PI-resistance mutations, it is associated with reduced susceptibility
	to LPV, ATV, and DRV.
NRTI	D67N is a non-polymorphic TAM associated with low-level resistance to AZT.
	K219E/Q/N/R are accessory TAMS that usually occur in combination with multiple other
	TAMs.
	K70R is a TAM that confers intermediate resistance to AZT and contributes to reduced
	ABC and TDF susceptibility in combination with other TAMs.
	M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate
	resistance to ABC (3-fold reduced susceptibility). M184V/I are not contraindications to
	continued treatment with 3TC or FTC because they increase susceptibility to AZT and
	TDF and are associated with clinically significant reductions in HIV-1 replication.
NNRTI	
INSTI	